MedTrace Logo

Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL

NCT04240704 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-10-10

No results posted yet for this study

Summary

The purpose of the First-In-Human study was to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of JBH492 as single agent.

Conditions

Interventions

DRUG

JBH492

Anti-CCR7 antibody-drug conjugate (ADC)

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-07
Primary Completion
2024-09-05
Completion
2024-09-05
FDA Drug
Yes

Countries

  • Finland
  • Germany
  • Israel
  • Japan
  • Singapore
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04240704 on ClinicalTrials.gov